Advances in Targeting CD30 for Classic Hodgkin Lymphoma Therapy
LUO Xia, ZHANG Wenqian, LI Huijun, DENG Lingyan*
CD30, a member of TNFR (tumor necrosis factor receptor) superfamily, is a type I transmembrane protein that is localized to cell membrane. CD30 is only expressed in some activated B lymphocytes and T lymphocytes and involved in regulating the function of immune system. However, it is upregulated in a variety of lymphomas, especially in cHL (classical Hodgkin’s lymphoma). Highly expressed CD30 promotes cHL progression through various mechanisms, such as activation of NF-κB, MAPK-ERK signaling pathway, and influence of tumor microenvironment to promote the proliferation and anti-apoptosis of cHL tumor cells. As it is highly overexpressed in cHL tumors and promotes disease progression, CD30 is a promising therapeutic target for cHL. BV (Brentuximab vedotin), a kind of CD30 related antibody-drug conjugate, has been approved for the clinical treatment of relapsed/refractory cHL. The clinical indications of BV have been rapidly expanded and significantly improved the prognosis of cHL patients. In addition to BV, several studies are working to develop other CD30-targeted therapies for cHL, such as CD30 monoclonal antibodies and CD30 CAR-T cells. The effectiveness of these treatments has confirmed by many preclinical studies and clinical trials. This review will summarize the expression and function of CD30 in cHL and cover the advances in targeting CD30 for cHL.
CN
EN